Przejdź do zawartości
Merck

Concurrent access to nicotine and sucrose in rats.

Psychopharmacology (2014-11-05)
Leigh V Panlilio, Lee Hogarth, Mohammed Shoaib
ABSTRAKT

Animal models that allow concurrent access to drug and nondrug reinforcers provide unique insight into the etiology, maintenance, and treatment of drug use. We sought to develop and utilize a concurrent access procedure with nicotine and sucrose in rats. Pressing one lever delivered intravenous nicotine, and pressing another lever delivered sucrose pellets, with both reinforcers freely available throughout daily sessions. Rats that had been pretrained with nicotine on some days and sucrose on other days responded on both levers when subsequently given concurrent access, but almost all responded at substantially higher rates on the sucrose lever. In contrast, rats pretrained exclusively with nicotine before being given concurrent access showed individual differences, with about half responding more on the nicotine lever. Treatment with the nicotinic receptor partial agonist varenicline selectively decreased nicotine self-administration. Food restriction and removal of the sucrose lever both increased nicotine self-administration. The finding that rats continue to take nicotine when sucrose is concurrently available-and in many cases take it more frequently than sucrose-demonstrates that nicotine self-administration does not only occur in the absence of alternative reinforcement options. As a model of human nicotine use, concurrent access is more naturalistic and has higher face validity than procedures in which only one reinforcer is available or choosing one reinforcer precludes access to other reinforcers. As such, this procedure could be useful for evaluating therapeutic agents and improving our understanding of environmental conditions that promote or discourage nicotine use.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Supelco
Sucrose, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Sucrose, puriss., meets analytical specification of Ph. Eur., BP, NF
Sigma-Aldrich
Sucrose, BioUltra, Molecular Biology, ≥99.5% (HPLC)
Millipore
Sucrose, suitable for microbiology, ACS reagent, ≥99.0%
Sigma-Aldrich
Enrofloxacin, ≥99.0%
Sigma-Aldrich
Sucrose, Molecular Biology, ≥99.5% (GC)
Sigma-Aldrich
Sucrose, ≥99.5% (GC)
Sigma-Aldrich
Sucrose, ACS reagent
Sigma-Aldrich
(±)-Nicotine, ≥99% (TLC), liquid
Sigma-Aldrich
Sucrose, meets USP testing specifications
Sigma-Aldrich
Sucrose, ≥99.5% (GC), BioXtra
Sigma-Aldrich
Sucrose, ≥99% (GC), Grade I, suitable for plant cell culture
Sigma-Aldrich
Sucrose, ≥99.5% (GC), Grade II, suitable for plant cell culture
Sucrose, European Pharmacopoeia (EP) Reference Standard
USP
Sucrose, United States Pharmacopeia (USP) Reference Standard
Supelco
Enrofloxacin, VETRANAL®, analytical standard
Sigma-Aldrich
Sucrose, ≥99.5% (GC), BioReagent, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
Sucrose, ≥99.5% (GC)
Supelco
Sucrose, analytical standard, for enzymatic assay kit SCA20
Enrofloxacin, European Pharmacopoeia (EP) Reference Standard
USP
Enrofloxacin, United States Pharmacopeia (USP) Reference Standard
Supelco
Enrofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
(−)-Nicotine, ≥99% (GC), liquid
Supelco
(−)-Nicotine, PESTANAL®, analytical standard
Enrofloxacin for system suitability, European Pharmacopoeia (EP) Reference Standard